Sign In
Buy RCUS
$28.42
-1.31 (-4.41%)
At Close: Jul 24, 2026
SMMT Shares Updated Ivonescimab Survival Data From NSCLC Study
11:36am, Thursday, 23'rd Jul 2026
Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab in kidney cancer, expanding its late-stage development.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)---- $SMMT--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combinat
HAYWARD, Calif. & MIAMI--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therap
Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
04:05pm, Tuesday, 21'st Jul 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
Why Did This Arcus Biosciences Analyst Bump Price Forecast by 33%?
02:45pm, Monday, 20'th Jul 2026
HC Wainwright raised its price forecast for Arcus Biosciences Inc. (NASDAQ:RCUS), citing the aggressive push into 1L clear cell renal cell carcinoma (ccRCC) development.
An Arcus Insider Sold 68,569 Shares but Kept 1.2 Million After a 200% Run
07:09pm, Monday, 13'th Jul 2026
This sale was executed under a Rule 10b5-1 plan following a 203% one-year surge.
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Thursday, 09'th Jul 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
11:00am, Wednesday, 01'st Jul 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Wednesday, 24'th Jun 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
09:02pm, Tuesday, 09'th Jun 2026
Arcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Arcus Biosciences Announces New Employment Inducement Grants
04:35pm, Tuesday, 09'th Jun 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for p
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
12:55pm, Thursday, 04'th Jun 2026
Arcus Biosciences teams up with Bristol Myers Squibb to test casdatifan combinations in kidney cancer, expanding its ccRCC development strategy.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
04:05pm, Tuesday, 26'th May 2026
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patient
